| Literature DB >> 28194710 |
Sandrine Colas1, Assia Allalou2, Antoine Poichotte3, Philippe Piriou4, Rosemary Dray-Spira2, Mahmoud Zureik2.
Abstract
BACKGROUND: Exchangeable neck stems, defined as those with a dual taper (that is, a modular junction between the femoral head and the femoral neck and an additional junction between the neck and the stem body), were introduced in THA to improve restoration of joint biomechanics (restoring anteversion, offset, and limb length) and reduce the risk of dislocation. However exchangeable necks have been reported to result in adverse effects such as stem fractures and acute local tissue reaction. Whether they result in a net improvement to or impairment of reconstructive survivorship remains controversial. QUESTIONS/PURPOSES: (1) To compare the prosthetic survivorship and all-cause revision risk of exchangeable femoral neck THAs versus fixed neck THAs, taking known prosthetic revision risk factors into account; and (2) to compare the cause-specific revision risk of exchangeable femoral neck THAs versus fixed neck THAs, adjusting for known prosthetic risk factors.Entities:
Mesh:
Year: 2017 PMID: 28194710 PMCID: PMC5498370 DOI: 10.1007/s11999-017-5260-6
Source DB: PubMed Journal: Clin Orthop Relat Res ISSN: 0009-921X Impact factor: 4.176
Fig. 1A flow chart of our study population is shown. PMSI = Programme de Médicalisation des Systèmes d’Information.
Fig. 2A–BAn (A) exchangeable femoral neck stem and (B) a fixed femoral neck stem are shown. An exchangeable femoral neck stem has a trunnion between the neck and ball head, and an additional trunnion between the neck and body of the stem. A fixed femoral neck stem has a trunnion only between the neck and ball head.
Baseline characteristics according to type of femoral neck
| Fixed neck (%) | Exchangeable neck (%) | p Value* | ||
|---|---|---|---|---|
| Covariates | Number | (n = 315,177) | (n = 8931) | |
| THA characteristics | ||||
| Cement type† | < 0.001 | |||
| Cemented | 34,376 | 11 | 3 | |
| Hybrid | 53,611 | 17 | 9 | |
| Reverse hybrid | 5040 | 2 | 2 | |
| Uncemented | 231,081 | 71 | 86 | |
| Bearing surface | < 0.001 | |||
| CoC | 104,584 | 32 | 46 | |
| CoP | 56,055 | 17 | 14 | |
| MoM | 8667 | 3 | 6 | |
| MoP | 154,802 | 48 | 35 | |
| Patient characteristics | ||||
| Sex | < 0.001 | |||
| Male | 122,178 | 38 | 42 | |
| Female | 201,930 | 62 | 58 | |
| Age category (years) | < 0.001 | |||
| 40–59 | 46,945 | 14 | 21 | |
| 60–74 | 122,590 | 38 | 43 | |
| ≥ 75 | 154,573 | 48 | 37 | |
| Trauma indication | 77,168 | 24 | 16 | < 0.001 |
| Parkinson disease | 13,158 | 4 | 3 | < 0.001 |
| Diabetes mellitus | 40,475 | 13 | 13 | 0.18 |
| Morbid obesity | 24,678 | 8 | 8 | 0.03 |
| Treatments | ||||
| Benzodiazepine | 163,289 | 50 | 50 | 0.24 |
| AH no BZD | 45,534 | 14 | 14 | 0.37 |
| Antidepressant | 73,418 | 23 | 21 | < 0.001 |
| Antipsychotic | 22,364 | 7 | 6 | < 0.001 |
| Psychostimulant | 3386 | 1 | 1 | 0.62 |
| Antiosteoporotic | 42,311 | 13 | 12 | 0.02 |
| Oral corticosteroïds | 83,198 | 26 | 27 | 0.02 |
| Hospital characteristics | ||||
| Sector | < 0.001 | |||
| Public | 136,853 | 41 | 71 | |
| Private | 187,255 | 59 | 29 | |
| Number of THAs per month | < 0.001 | |||
| < 14 | 93,647 | 49 | 42 | |
| 14–38 | 158,262 | 29 | 33 | |
| > 38 | 72,199 | 22 | 25 | |
| Hospital stay duration (days) | < 0.001 | |||
| < 6 | 15,952 | 78 | 82 | |
| 6–12 | 254,695 | 5 | 5 | |
| > 12 | 53,461 | 17 | 13 | |
*Exchangeable versus fixed femoral neck THAs; †percentages for fixed neck cement types = 101% owing to rounding; CoC = ceramic-on-ceramic; CoP = ceramic-on-polyethylene; MoM = metal-on-metal; MoP = metal-on-polyethylene; AH no BZD = anxiolytic or hypnotic nonbenzodiazepines.
Fig. 3The cumulative incidence of revision THA according to the type of femoral neck is shown.
Associations among THA, patients, hospital stay characteristics, and THA revision
| Covariates | Values | Number | Revision (%) | HR | 95% CI | p Value | Adjusted HR*,† | 95% CI | p Value |
|---|---|---|---|---|---|---|---|---|---|
| THA characteristics | |||||||||
| Exchangeable neck | No | 315,177 | 3.7 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Yes | 8931 | 4.9 | 1.36 | (1.24–1.49) | 1.26 | (1.14–1.38) | |||
| THA cement type | Cemented | 34,376 | 3.0 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Hybrid | 53,611 | 2.9 | 0.94 | (0.87–1.02) | 0.99 | (0.92–1.08) | |||
| Reverse hybrid | 5040 | 4.5 | 1.52 | (1.32–1.76) | 1.53 | (1.33–1.77) | |||
| Uncemented | 231,081 | 4.0 | 1.31 | (1.23–1.40) | 1.31 | (1.22–1.40) | |||
| Bearing surface | CoC | 104,584 | 4.0 | 1.12 | (1.07–1.16) | < 0.0001 | 1.07 | (1.01–1.13) | < 0.001 |
| CoP | 56,055 | 3.5 | 0.99 | (0.94–1.04) | 1.02 | (0.96–1.08) | |||
| MoM | 8667 | 5.0 | 1.30 | (1.18–1.44) | 1.25 | (1.12–1.38) | |||
| MoP | 154,802 | 3.5 | 1 | Reference | 1 | Reference | |||
| Patient characteristics | |||||||||
| Sex | Male | 122,178 | 3.8 | 1.05 | (1.02–1.09) | 0.004 | 1.09 | (1.05–1.14) | < 0.001 |
| Female | 201,930 | 3.6 | 1 | Reference | 1 | Reference | |||
| Age category (years) | 40–59 | 46,945 | 4.7 | 1.24 | (1.17–1.30) | < 0.0001 | 1.19 | (1.13–1.25) | < 0.001 |
| 60–74 | 122,590 | 3.8 | 1 | Reference | 1 | Reference | |||
| ≥ 75 | 154,573 | 3.3 | 0.89 | (0.85–0.92) | 0.86 | (0.82–0.90) | |||
| Trauma indication | No | 246,940 | 3.7 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Yes | 77,168 | 3.8 | 1.09 | (1.05–1.14) | 1.12 | (1.06–1.19) | |||
| Parkinson disease | No | 310,950 | 3.6 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Yes | 13,158 | 4.9 | 1.39 | (1.28–1.50) | 1.26 | (1.16–1.37) | |||
| Diabetes mellitus | No | 283,633 | 3.7 | 1 | Reference | 0.24 | 1 | Reference | 0.491 |
| Yes | 40,475 | 3.8 | 1.03 | (0.98–1.09) | 1.02 | (0.97–1.08) | |||
| Morbid Obesity | No | 299,430 | 3.6 | 1 | Reference | 0.0004 | 1 | Reference | < 0.001 |
| Yes | 24,678 | 4.2 | 1.16 | (1.09–1.24) | 1.14 | (1.07–1.22) | |||
| Treatments | |||||||||
| BZD | No | 160,819 | 3.0 | 1 | Reference | < 0.0001 | < 0.001 | ||
| Yes | 163,289 | 4.4 | 1.42 | (1.37–1.47) | 1.28 | (1.23–1.33) | |||
| AH no BZD | No | 278,574 | 3.5 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Yes | 45,534 | 4.9 | 1.43 | (1.36–1.49) | 1.24 | (1.18–1.30) | |||
| Antidepressant | No | 250,690 | 3.4 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Yes | 73,418 | 4.9 | 1.47 | (1.41–1.53) | 1.31 | (1.25–1.37) | |||
| Antipsychotic | No | 301,744 | 3.6 | 1 | Reference | < 0.0001 | 1 | Reference | 0.348 |
| Yes | 22,364 | 4.6 | 1.30 | (1.22–1.39) | 1.03 | (0.97–1.11) | |||
| Psychostimulant | No | 320,722 | 3.7 | 1 | Reference | 0.31 | 1 | Reference | 0.769 |
| Yes | 3386 | 4.2 | 1.09 | (0.92–1.29) | 1.03 | (0.87–1.21) | |||
| Antiosteoporotic | No | 281,797 | 3.7 | 1 | Reference | 0.02 | 1 | Reference | 0.008 |
| Yes | 42,311 | 3.9 | 1.06 | (1.01–1.12) | 1.08 | (1.02–1.14) | |||
| Oral corticcosteroïds | No | 240,910 | 3.5 | 1 | Reference | < 0.0001 | 1 | Reference | < 0.001 |
| Yes | 83,198 | 4.2 | 1.20 | (1.15–1.25) | 1.13 | (1.09–1.18) | |||
| Hospital stay characteristics | |||||||||
| Sector | Public | 136,853 | 3.7 | 1.05 | (1.01–1.08) | 0.02 | 1.02 | (0.98–1.06) | 0.453 |
| Private | 187,255 | 3.7 | 1 | Reference | 1 | Reference | |||
| Number of procedures per month | < 14 | 93,647 | 3.7 | 1.20 | (1.14–1.27) | < 0.0001 | 1.18 | (1.12–1.24) | < 0.001 |
| 14–38 | 158,262 | 4.0 | 1.09 | (1.04–1.15) | 1.09 | (1.04–1.14) | |||
| > 38 | 72,199 | 3.3 | 1 | Reference | 1 | Reference | |||
| Hospital. stay duration (days) | < 6 | 15,952 | 3.7 | 0.99 | (0.91–1.08) | 0.001 | 1.00 | (0.92–1.09) | 0.198 |
| 6–12 | 254,695 | 3.4 | 1 | Reference | 1 | Reference | |||
| > 12 | 53,461 | 4.0 | 1.09 | (1.04–1.15) | 1.05 | (1.00–1.10) | |||
*p value class versus reference; †adjusted hazard ratio of THA revision from multivariate Fine and Gray full regression model (adjusted for THA characteristics, patient characteristics, treatments, and hospital stay characteristics); HR = hazard ratio; CoC = ceramic-on-ceramic; CoP = ceramic-on-polyethylene; MoM = metal-on-metal; MoP = metal-on-polyethylene; BZD = benzodiazepine; AH no BZD = anxiolytic or hypnotic nonbenzodiazepines.
Comparison of overall and cause-specific risks of THA revision according to type of THA femoral neck
| Cause of revision | Frequency of THA revision | p Value | Cause-specific | p Value | ||||
|---|---|---|---|---|---|---|---|---|
| Patients with fixed neck (n = 315,177 [97%]) | Patients with exchangeable neck (n = 8931 [3%]) | Risk of revision associated with type of femoral neck | ||||||
| Number | Percent | Number | Percent | Adjusted HR* | 95% HR CI | |||
| All-cause | 11,968 | 3.7 | 442 | 4.9 | < 0.001 | 1.26 | 1.14–1.38 | < 0.001 |
| Periprosthetic fracture or implant failure | 1050 | 0.3 | 45 | 0.5 | < 0.001 | 1.68 | 1.24–2.27 | < 0.001 |
| Dislocation | 2644 | 0.8 | 86 | 1.0 | 0.117 | 1.15 | 0.92–1.42 | 0.222 |
| Infection | 1345 | 0.4 | 37 | 0.4 | 0.992 | 0.95 | 0.69–1.33 | 0.954 |
| Mechanical complication | 7817 | 2.4 | 300 | 3.4 | < 0.001 | 1.27 | 1.13–1.43 | < 0.001 |
| Other | 285 | 0.1 | 15 | 0.1 | 0.052 | 1.62 | 0.96–2.76 | 0.073 |
Sum of different causes of revision (n = 13,141) > number of all-cause revisions (n = 11,968) because each revision could have multiple causes; *cause-specific adjusted hazard ratio of THA revision from multivariate Cox full model (adjusted for THA characteristics, patient characteristics, treatments, and hospital stay characteristics); HR = hazard ratio.
Registry and literature data for exchangeable and fixed femoral neck THA revision rates and risk
| Source | Data period | Implant type | Cumulative revision rate (%)[95% CI] | Average followup (years) | Hazard ratio exchangeable vs fixed implant [95% CI] |
|---|---|---|---|---|---|
| Number of THAs | |||||
| Australian Orthopaedic Association National Joint Replacement Registry [ | 2006–2014 | All THA | 1.6 [1.6–1.7] | 1 | |
| 3.9 [3.9–4.0] | 5 | ||||
| 5.2 [5.1–5.3] | 7 | ||||
| 6.8 [6.7–6.9] | 10 | ||||
| Exchangeable neck | 8.3 [7.5–9.2] | 7 | 2.04 [1.87–2.22] | ||
| Fixed neck | 3.7 [3.6–3.8] | 7 | 1.00 [reference] | ||
| Swedish Hip Register, [ | 1979–2014 | All THA* | 6.2 [5.9–6.5] | 10 | NP |
| New Zealand Joint Registry [ | 1999–2012 | All THA* | 1.3 [NP] | 1 | NP |
| 3.3 [NP] | 5 | ||||
| 4.5 [NP] | 7 | ||||
| 6.9 [NP] | 10 | ||||
| National Joint Registry for England, Wales and Northern Ireland [ | All THA* | 0.8 [0.7–0.8] | 1 | ||
| 2.7 [2.7–2.8] | 5 | ||||
| 4.0 [3.9–4.1] | 7 | ||||
| 5.8 [5.6–5.9] | 10 | ||||
| The Norwegian Arthroplasty Registry, [ | 1987–2014 | All THA* | 6.9 [6.6–7.2] | 10 | NP |
| Canadian Joint Replacement Registry [ | 2008–2013 | All THA* | NP | NP | NP |
| Netherlands Arthroplasty Register [ | 2007–2012 | All THA* | NP | NP | NP |
| Mihalko et al. [ | Total = NP | Exchangeable neck#
| 0 to 9% [NP] | 10 to 19 | NP |
| Exchangeable neck#
| 16% [NP] | 17 | NP | ||
| Meftah et al. [ | Total = 123 | Exchangeable neck#
| 28% [NP] | 3 | NP |
| Silverton et al. [ | Total = 152 | Exchangeable neck#
| 10.6% [NP] | 4.5 | NP |
| Regis et al. [ | Total = 168 | Exchangeable neck | 9.1%§ | 2 | NP |
| Fixed neck | 6.8%§
| ||||
| Gerhardt et al. [ | Total = 190 | Exchangeable neck | 4%§ | 1 | NP |
| Fixed neck | 4%§
| ||||
| Fitch et al. [ | Total = NP | Exchangeable neck | 4.2% [2.6-5.8] | 12 | NP |
| Fixed neck | 3.9% [NP] | ||||
| Ollivier et al. [ | Total = NP | Exchangeable neck#
| NP | 6 | NP |
| Duwelius et al. [ | Total = 878 | Exchangeable neck | 1% [0–2] | 2 | NP |
| Fixed neck | 1% [0–3] | ||||
| (p = 0.94) |
*Cumulative revision rates for exchangeable neck only, and for fixed neck only not provided, which makes comparison impossible;#cumulative revision rate for fixed femoral neck not provided, which makes comparison impossible; §cumulative risk for dislocation as outcome; NP = not provided